{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:37:28Z","timestamp":1761514648944,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.cllc.2020.09.011","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T11:37:31Z","timestamp":1600429051000},"page":"32-41.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Characteristics, Treatments, and Concurrent Mutations in Non\u2013Small Cell Lung Cancer Patients With NF1 Mutations"],"prefix":"10.1016","volume":"22","author":[{"given":"Lee","family":"Bowman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Nash","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda Dale","family":"Willard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7331-2625","authenticated-orcid":false,"given":"Julie","family":"Beyrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-7507","authenticated-orcid":false,"given":"Ambrish","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.09.011_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2020.09.011_bib3","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/modpathol.2011.215","article-title":"Molecular pathology of lung cancer: key to personalized medicine","volume":"25","author":"Cheng","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2020.09.011_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2020.09.011_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3332\/ecancer.2017.787","article-title":"Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come","volume":"11","author":"Toschi","year":"2017","journal-title":"Ecancermedicalscience"},{"year":"2018","series-title":"Evolution of Cancer Treatments: Targeted Therapy","key":"10.1016\/j.cllc.2020.09.011_bib7"},{"key":"10.1016\/j.cllc.2020.09.011_bib8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.6004\/jnccn.2018.0062","article-title":"NCCN guidelines insights: non-small cell lung cancer, Version 5.2018","volume":"16","author":"Ettinger","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2020.09.011_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2020.09.011_bib10","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.09.011_bib11","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1200\/JCO.2009.23.6661","article-title":"EML4-ALK: honing in on a new target in non-small-cell lung cancer","volume":"27","author":"Horn","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib12","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/modpathol.2009.2","article-title":"EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset","volume":"22","author":"Inamura","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2020.09.011_bib14","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1158\/1078-0432.CCR-15-2377","article-title":"Clinical and molecular characteristics of NF1-mutant lung cancer","volume":"22","author":"Redig","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.09.011_bib15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cllc.2020.09.011_bib16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib17","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/annonc\/mdt220","article-title":"The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/PAS.0b013e3182758fe6","article-title":"ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases","volume":"37","author":"Yoshida","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cllc.2020.09.011_bib19","doi-asserted-by":"crossref","first-page":"4227s","DOI":"10.1158\/1078-0432.CCR-040007","article-title":"The biology of epidermal growth factor receptor in lung cancer","volume":"10","author":"Scagliotti","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.09.011_bib20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2020.09.011_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2020.09.011_bib22","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"Kosaka","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2020.09.011_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New driver mutations in non-small-cell lung cancer","volume":"12","author":"Pao","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1056\/NEJM199008303230902","article-title":"K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung","volume":"323","author":"Slebos","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.09.011_bib25","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.09.011_bib26","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A\u00a0comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2020.09.011_bib27","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1158\/1078-0432.CCR-09-0089","article-title":"EGFR\/KRAS\/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases","volume":"15","author":"Schmid","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2020.09.011_bib28","doi-asserted-by":"crossref","first-page":"e88291","DOI":"10.1371\/journal.pone.0088291","article-title":"PIK3CA mutations frequently coexist with EGFR\/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR\/KRAS wildtype subgroup","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2020.09.011_bib29","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJM198710083171504","article-title":"Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung","volume":"317","author":"Rodenhuis","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.09.011_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.bjc.6602258","article-title":"The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis","volume":"92","author":"Mascaux","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2020.09.011_bib32","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2012.48.1390","article-title":"Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy","volume":"31","author":"Shepherd","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/JTO.0b013e318283d958","article-title":"KRAS mutations as prognostic and predictive markers in non-small cell lung cancer","volume":"8","author":"Martin","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2018.04.006","article-title":"BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall","volume":"66","author":"Leonetti","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cllc.2020.09.011_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oxfordjournals.aje.a010118","article-title":"NF1 gene and neurofibromatosis 1","volume":"151","author":"Rasmussen","year":"2000","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cllc.2020.09.011_bib36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/351576a0","article-title":"Differential regulation of rasGAP and neurofibromatosis gene product activities","volume":"351","author":"Bollag","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2020.09.011_bib37","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2020.09.011_bib38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2020.09.011_bib39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fonc.2014.00204","article-title":"Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS","volume":"4","author":"Korpanty","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bjc.6603227","article-title":"A\u00a0prospective study of neurofibromatosis type 1 cancer incidence in the UK","volume":"95","author":"Walker","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2020.09.011_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4174\/jkss.2012.82.4.205","article-title":"Oncologic manifestations of neurofibromatosis type 1 in Korea","volume":"82","author":"Kim","year":"2012","journal-title":"J\u00a0Korean Surg Soc"},{"year":"2018","series-title":"LifeScience","key":"10.1016\/j.cllc.2020.09.011_bib42"},{"year":"2017","series-title":"Unleashing the potential of clinico-genomic information: ASCO 2017","author":"Singal","key":"10.1016\/j.cllc.2020.09.011_bib43"},{"issue":"15 Suppl","key":"10.1016\/j.cllc.2020.09.011_bib44","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.35.15_suppl.2514","article-title":"Development and validation of a real-world clinicogenomic database","volume":"35","author":"Singal","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib45","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2217\/fon-2015-0043","article-title":"Opportunities and challenges in leveraging electronic health record data in oncology","volume":"12","author":"Berger","year":"2016","journal-title":"Future Oncol"},{"year":"2016","key":"10.1016\/j.cllc.2020.09.011_bib46","article-title":"Exploring the Utility of Real World Evidence (RWE) - Pre-Meeting Draft White Paper"},{"key":"10.1016\/j.cllc.2020.09.011_bib47","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s00432-019-03001-2","article-title":"Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC","volume":"145","author":"Deng","year":"2019","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib48","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high-quality composite real-world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Serv Res"},{"key":"10.1016\/j.cllc.2020.09.011_bib49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2020.09.011_bib50","doi-asserted-by":"crossref","first-page":"S779","DOI":"10.21037\/tcr.2018.08.11","article-title":"Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors","volume":"7","author":"Sehgal","year":"2018","journal-title":"Transl Cancer Res"},{"year":"2016","series-title":"FDA approves crizotinib capsules","author":"US Food and Drug Administration","key":"10.1016\/j.cllc.2020.09.011_bib51"},{"key":"10.1016\/j.cllc.2020.09.011_bib52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijrobp.2019.01.017","article-title":"Correlation of survival outcomes with clinical and molecular features in lung cancer patients treated with immune checkpoint inhibitors","volume":"104","author":"Chen","year":"2019","journal-title":"Int J Rad Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib53","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ijc.31871","article-title":"Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients","volume":"144","author":"Pan","year":"2019","journal-title":"Int J Cancer"},{"issue":"Suppl 10","key":"10.1016\/j.cllc.2020.09.011_bib54","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/j.jtho.2018.08.560","article-title":"P1.01-04 Treatment patterns and overall survival following biomarker testing in real-world advanced NSCLC patients","volume":"13","author":"Barlesi","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib55","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2018.08.004","article-title":"24-Month overall survival from KEYNOTE-021 Cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer","volume":"14","author":"Borghaei","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2020.09.011_bib56","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3389\/fonc.2019.00953","article-title":"New horizons in KRAS-mutant lung cancer: dawn after darkness","volume":"9","author":"Yang","year":"2019","journal-title":"Front Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420302758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420302758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:23Z","timestamp":1761505823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420302758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1525730420302758"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.09.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Characteristics, Treatments, and Concurrent Mutations in Non\u2013Small Cell Lung Cancer Patients With NF1 Mutations","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}